A new study by an international team of investigators led by Dana-Farber Cancer Institute scientists is the first to demonstrate that chemotherapy and a new, targeted drug - selumetinib, work better in combination than chemotherapy alone in a clinical trial involving patients with a form of non-small cell lung cancer (NSCLC) that carries a mutation in the gene KRAS. Previously, no targeted agent, either alone or in combination with another drug, had proven beneficial in a study involving patients with this type of NSCLC. The study results were published in The Lancet Oncology. Read more here.
Study mentioned: Janne PA, et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. The Lancet Oncology, Early online publication, 28 November 2012.
No comments:
Post a Comment